BioAegis raises $3 million

02/8/2013 | American City Business Journals

A funding round has brought in $3 million for biotech startup BioAegis Therapeutics. The company plans to file an investigational new-drug application with the FDA and launch a Phase IIb/III study of human plasma gelsolin, a natural human protein, in preventing the spread of inflammation resulting in multiple organ dysfunction syndrome in intensive care units.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ